US OptionsDetailed Quotes

BGNE240517C165000

Watchlist

4.00
0.000.00%

15min DelayTrading May 16 09:58 ET

0.00High0.00Low

BeiGene Stock Discussion

Meltyy

May 16 01:14

🔔 Baker Bros. Q1 ‘24* Holdings Released... 🐳

» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US)$
$BeiGene(BGNE.US)$
$ACADIA Pharmaceuticals(ACAD.US)$
$Madrigal Pharmaceuticals(MDGL.US)$
$Rhythm Pharmaceuticals(RYTM.US)$
$Revolution Medicines(RVMD.US)$
$Kymera Therapeutics(KYMR.US)$
$AbCellera Biologics(ABCL.US)$
$Bicycle Therapeutics(BCYC.US)$
$Edgewise Therapeutics(EWTX.US)$
$Immunocore(IMCR.US)$
$Kodiak Sciences(KOD.US)$
$Roivant Sciences(ROIV.US)$
...

Meltyy

Mar 11 22:36

4 PDUFA decisions this week!

Last week’s PDUFAs:
$BeiGene(BGNE.US)$ : Approved 3/8 🎉
⇒ BRUKINSA + obinutuzumab
⇒ Follicular Lymphoma
⇒ sNDA
⇒ PDUFA date: Mar 2024
$Bristol-Myers Squibb(BMY.US)$ : Approved 3/8 🎉
⇒ Opdivo ® + Cisplatin & Gemcitabine
⇒ Urothelial carcinoma
⇒ sBLA
⇒ PDUFA: 04/05/24
$Vanda Pharmaceuticals(VNDA.US)$ : CRL 3/4 🙁
⇒ HETLIOZ®
⇒ insomnia
⇒ sNDA
⇒ PDUFA: 03/04/24
$Eyenovia(EYEN.US)$ : Approved 3/4 🎉
⇒ Clobetasol propionate ophthalmic susp. 0.05% (APP13007)
⇒ postop eye pa...

Meltyy

Feb 27 21:34

FDA Calendar-March

The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
$Eyenovia(EYEN.US)$ $Vanda Pharmaceuticals(VNDA.US)$ $Mirum Pharmaceuticals(MIRM.US)$ $Madrigal Pharmaceuticals(MDGL.US)$ $Geron(GERN.US)$ $Bristol-Myers Squibb(BMY.US)$ $2seventy bio(TSVT.US)$ $Legend Biotech(LEGN.US)$ $OptiNose(OPTN.US)$ $Orchard Therapeutics(ORTX.US)$ $Merck & Co(MRK.US)$ $Akebia Therapeutics(AKBA.US)$ $AstraZeneca(AZN.US)$ $Liquidia(LQDA.US)$ $Esperion Therapeutics(ESPR.US)$ $Regeneron Pharmaceuticals(REGN.US)$ $BeiGene(BGNE.US)$

Kevin Travers

Feb 27 10:02

ColumnsBiotechnology Stocks Climbing on Earnings and Test Results: What to Watch

$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks.
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...

AlanYeo

Feb 7 03:18

CIMB: Healthcare Overall – Overweight

The research is done by the respective broker and I do not endorse any of them. Just sharing here for information and reading pleasure.
alphaedgeinvest...
$BEIGENE(06160.HK)$ $BeiGene(BGNE.US)$

Moomoo AI

Feb 5 06:42

The market's expectation of a decline in future revenue performance could be keeping BeiGene's P/S ratio low. Despite potential for share price to match revenue if current course is maintained, the company's inferior revenue outlook may suggest limited future growth to investors.

Benign Growth For BeiGene, Ltd. (NASDAQ:BGNE) Underpins Its Share Price

AlanYeo

Jan 23 20:22

China Galaxy: BeiGene Ltd – Initiate coverage with an Add rating, Target Price HK$169.70

The research is done by the respective broker and I do not endorse any of them. Just sharing here for information and reading pleasure.
China Galaxy: BeiGene Ltd – Initiate coverage with an Add rating, Target Price HK$169.70 - Alpha Edge Investing
$BEIGENE(06160.HK)$ $BeiGene(BGNE.US)$

Moomoo AI

Jan 18 07:13

BeiGene's cash surplus suggests safe debt management. However, future profitability will determine balance sheet strength. Despite being pre-profit, its revenue growth indicates potential profitability.

Rock Star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt

Spinee

Jan 17 02:21

HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off

$Hang Seng Index(800000.HK)$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN(09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH(01873.HK)$ ...

Bamboo Works

Dec 22, 2023 01:06

ColumnsHBM gets health boost from drug licensing deals

HBM gets health boost from drug licensing deals
December 22, 2023
2142.HK
1.56
(-2.5%)
The biopharma company has marked out a path to profitability by licensing its drug expertise and antibody platforms to partners such as Pfizer
Key Takeaways:
Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with a Pfizer-owned biotech for an initial sum of $53 million and milestone payments of up to $1.05 billion
HBM Holdin...

No comment yet